<DOC>
	<DOCNO>NCT01472146</DOCNO>
	<brief_summary>The purpose study evaluate association zoledronic acid standard treatment anthracycline follow taxane plus trastuzumab locally advanced breast cancer HER 2 positive .</brief_summary>
	<brief_title>ZoNantax - Zolendronic Acid Neoadjuvant Therapy Plus Anthracycline Taxane Locally Advanced Breast Cancer</brief_title>
	<detailed_description>This trial combine zolendronic acid anthracycline follow taxane plus trastuzumab neoadjuvant treatment HER 2 positive stage II/III breast cancer . Zoledronic acid ( ZOL ) activity anti-bone resorption show diverse anti-tumor effect vitro . Some chemical biological characteristic ZOL indicate potential inhibition tumor growth pre clinical study The primary objective study evaluate residual cancer burden ( RCB ) addition zolendronic acid standard neoadjuvant therapy . RCB calculate continuous index combine pathologic measurement primary tumor ( size cellularity ) nodal metastasis ( number size ) . RCB index significant predictor distant relapse-free survival , use define category near-complete response chemotherapy resistance neoadjuvant chemotherapy compare currently use risk factor . Additionally , study collect tissue biopsy blood treatment order correlate clinical outcome gene expression radiologic data predictive response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Stage IIA IIIB HER2 positive breast cancer 2 . ECOG performance ≤ 2 3 . Adequate hematologic function : Absolute neutrophil count ( ANC ) &gt; 1500/mm³ Platelets ≥ 100.000/mm³ hemoglobin ≥ 9g/dL 4 . Adequate hepatic renal function : Serum bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x institutional upper limit normal ( ULN ) Alkaline phosphatase ) ≤ 2.5 x institutional upper limit normal ( ULN ) Serum creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) calculate creatinine clearance &gt; 50 mL/min 5 . Adequate cardiac function Left ventricular ejection fraction ( LVEF ) institutional normal range 6 . Knowledge investigational nature study ability provide consent study participation 1 . Previous diagnostic breast cancer 2 . Pregnancy 3 . Metastatic breast cancer 4 . Bilateral , synchronous breast cancer 5 . Any disease ( ) , psychiatric condition , metabolic dysfunction , contraindicate use study drug woud make patient inappropriate study 6 . Neuropathy grade &gt; 2 Common Terminology Criteria Adverse Events version 3.0 ( CTCAE v3.0 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Neoadjuvant therapy</keyword>
	<keyword>Breast cancer HER2 positive</keyword>
	<keyword>zolendronic acid</keyword>
</DOC>